novo nordisk semaglutide patent New Delhi, March 19, 2026 – On Friday, the key on semaglutide—the active molecule in Nordisk's blockbuster drugs Ozempic and Wegovy—expired in India, marking a pivotal shift in the country's Ozempic's Key Molecule To Go

32 observed a small increase (3 mm Hg) in the systolic blood pressure of seven subjects considered to be responders with no significant increase relative to all subjects

Once in the brain it acts as a neuroprotective and antioxidant agent and supports energy metabolism

If you're experiencing side effects that concern you, contact your provider immediately

Oil barons didnt build Dallas by waiting for perfect conditions but by drilling when they recognized opportunity beneath surface

Confirm the tier and cost-share with CareFirst and ensure the required documentation of prior weight-loss attempts is prepared before submitting PA